Strategic Intelligence: Asia Beyond China: Pharma R&D and Deal Trends in South Korea, Japan, and India
Description
Strategic Intelligence: Asia Beyond China: Pharma R&D and Deal Trends in South Korea, Japan, and India
Summary
China continues to lead Asia’s drug development, with other nations following China’s initiatives.
Small molecules and oncology remain as the most dominant within Asian drug development markets.
South Korea and India expand clinical trial activity while Japan shifts to multinational trials.
M&A occurs but remains a secondary channel to licensing across these markets; South Korea and Japan are primarily oriented toward out-licensing innovative assets to US/EU partners.
Scope
Summary
China continues to lead Asia’s drug development, with other nations following China’s initiatives.
Small molecules and oncology remain as the most dominant within Asian drug development markets.
South Korea and India expand clinical trial activity while Japan shifts to multinational trials.
M&A occurs but remains a secondary channel to licensing across these markets; South Korea and Japan are primarily oriented toward out-licensing innovative assets to US/EU partners.
Scope
- This report talks about how other nations, including South Korea, Japan, and India, are following China's initiatives by enhancing innovation across the drug development lifecycle.
- These nations are deploying differentiated regulatory pathways to accelerate development and attract investment, increasing Asia’s strategic importance for global clinical, regulatory, and partnering strategies.
Table of Contents
50 Pages
- Executive Summary
- Introduction
- China Paved the Way for Regulatory Advancements Across Asian Markets
- China Clearly Leads Asia's Innovator Drug Development
- Focus on Innovator Drugs Differs Across Asian Markets
- South Korea and India Skew Towards Early-Stage Supply with Japan Concentrating on Phase I-III Drug Development
- After China, South Korea Leads Small Molecule Pipeline Activity, with mAbs Next, Driven By Oncology
- Asian Markets Diversify Beyond Small Molecules with Distinct Modality Strengths
- Therapy Area Focus: Oncology
- Drug Development: Biosimilars
- Drug Development: Innovators
- China Dominates from a Clinical Trial Perspective Compared to South Korea, Japan, and India
- South Korea and India Expand Clinical Trial Activity While Japan Shifts to Multinational Trials
- China Clinical Trials: From Phase III Enrollment to Early Development Advantage
- South Korea Clinical Trials: Global Phase III Stronghold, Local Phase I Momentum
- Japan Clinical Trials: Phase III-Weighted, Evidence-Led Market for Approval and Access
- India: Late-Stage Scale for Big Pharma, Early-Stage Strength for Locals
- Clinical Trial Timelines Vary Across Asian Markets
- Excluding China, South Korea Is Driving Growth in Asia to US/EU Out-Licensing
- Out-Licensing Activity from South Korea and Japan Deepen Big Pharma Collaboration
- China Dominates Out-Licensing to the US/EU While South Korea and Japan Emerge as Key Secondary Sources
- Key Takeaways
- Abbreviations
- Related Reports
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
